SEC Comment Letter 0000000000-24-006624 to CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: June 10, 2024 · CIK: 0001962738 · Accession: 0000000000-24-006624

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-41666

Date

June 10, 2024

Author

Not clearly detected

Form

UPLOAD

Company

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)

Letter

United States securities and exchange commission logo June 10, 2024 Larry Zhang President and Principal Financial Officer CASI Pharmaceuticals, Inc. 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road, Chaoyang District, Beijing, 100025 People’s Republic of China Re:CASI Pharmaceuticals, Inc. Form 20-F for Fiscal Year Ended December 31, 2023 Filed March 28, 2024 File No. 001-41666 Dear Larry Zhang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
June 10, 2024
Larry Zhang
President and Principal Financial Officer
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road, Chaoyang District, Beijing, 100025
People’s Republic of China
Re:CASI Pharmaceuticals, Inc.
Form 20-F for Fiscal Year Ended December 31, 2023
Filed March 28, 2024
File No. 001-41666
Dear Larry Zhang:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io